Elypta nominated for Best Technological Innovation in Diagnostics by Medtech Insights
Elypta is a finalist in this year’s Medtech Insight Awards, an award that celebrates and recognizes excellence among the companies, teams, and individuals driving positive change across the global medtech industry.
Elypta is nominated for Best Technological Innovation: Diagnostics.
“We are delighted with this nomination,” says Karl Bergman, CEO of Elypta. “Accurate, rapid and cost-effective diagnostics are essential to fulfill the promise of precision medicine and we believe we need to find markers also in metabolism to achieve this. We are already gaining a great deal of interest in the US for our approach and this nomination will help raise our profile further.”
Elypta is a portfolio company to Chalmers Ventures